On the NSE, it zoomed 9.92% to close at ₹ 5,306.
Shares of Dr Reddy’s Laboratories jumped over 10% on Friday after the company said it has settled a litigation with a unit of Bristol Myers Squibb related to patents for Revlimid (lenalidomide) capsules, used in the treatment of cancer. Continuing its rally for the fourth consecutive day, the stock gained 10.36% to close at ₹ 5,326.70 on the BSE. During the day, it rose by 13.88% to ₹ 5,497 — its record high level. On the NSE, it zoomed 9.92% to close at ₹ 5,306. In traded volume terms, 6.37 lakh shares were traded at the BSE and over 2 crore units at the NSE during the day. The Hyderabad-based company has settled litigation with Celgene, a wholly-owned subsidiary of Bristol Myers Squibb, Dr Reddy’s Laboratories said in a statement on Thursday. In settlement of all outstanding claims in the litigation, Celgene has agreed to provide the company with a license to sell volume-limited amounts of generic lenalidomide capsules in the US, beginning on a confidential date after March 2022, subject to regulatory approval, it added. The agreed-upon percentages are confidential, Dr Reddy’s said.Shares of Dr Reddy’s Laboratories had risen in the last two days as Russia’s sovereign wealth fund RDIF will supply 100 million (10 crore) doses of Sputnik V COVID-19 vaccine to the drug maker upon getting regulatory approval in India. Meanwhile, the BSE healthcare index also rose 3.50% to close at 20,404.76.
You have reached your limit for free articles this month.
To get full access, please subscribe.
Already have an account ? Sign in
Show Less Plan
Subscription Benefits Include
Find mobile-friendly version of articles from the day’s newspaper in one easy-to-read list.
Move smoothly between articles as our pages load instantly.
Enjoy reading as many articles as you wish without any limitations.
A one-stop-shop for seeing the latest updates, and managing your preferences.
A select list of articles that match your interests and tastes.
We brief you on the latest and most important developments, three times a day.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
A letter from the Editor
Dear subscriber,Thank you!Your support for our journalism is invaluable. It’s a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.Suresh Nambath